title: Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation.
authors.forename: Joshua E
authors.initials: JE
authors.lastname: Allen
authors.forename: Wafik S
authors.initials: WS
authors.lastname: El-Deiry
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000187:drug effects*; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D053221:TNF-Related Apoptosis-Inducing Ligand; D000077150:Oxaliplatin; D048031:JNK Mitogen-Activated Protein Kinases